Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 3,785 shares of the company’s stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $11.95, for a total transaction of $45,230.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aduro Biotech, Inc. (NASDAQ:ADRO) opened at 12.30 on Friday. The firm’s market cap is $826.34 million. Aduro Biotech, Inc. has a 52-week low of $7.26 and a 52-week high of $23.06. The firm’s 50-day moving average is $11.71 and its 200-day moving average is $12.95.

Aduro Biotech (NASDAQ:ADRO) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.09. The firm earned $3.79 million during the quarter, compared to analyst estimates of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. The company’s revenue for the quarter was down 79.8% on a year-over-year basis. During the same quarter last year, the business posted $0.01 earnings per share. Analysts forecast that Aduro Biotech, Inc. will post ($1.35) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

WARNING: “Insider Selling: Aduro Biotech, Inc. (ADRO) VP Sells $45,230.75 in Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at http://www.watchlistnews.com/insider-selling-aduro-biotech-inc-adro-vp-sells-45230-75-in-stock/1061428.html.

A number of large investors have recently bought and sold shares of ADRO. BlackRock Fund Advisors raised its stake in Aduro Biotech by 62.0% in the second quarter. BlackRock Fund Advisors now owns 1,665,187 shares of the company’s stock valued at $18,833,000 after buying an additional 637,486 shares during the period. State Street Corp raised its stake in Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock valued at $6,147,000 after buying an additional 382,654 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Aduro Biotech by 133.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 511,784 shares of the company’s stock valued at $5,788,000 after buying an additional 292,264 shares during the period. Vanguard Group Inc. raised its stake in Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock valued at $20,300,000 after buying an additional 237,924 shares during the period. Finally, QVT Financial LP purchased a new stake in Aduro Biotech during the second quarter valued at $2,171,000. Institutional investors own 35.55% of the company’s stock.

A number of brokerages recently issued reports on ADRO. FBR & Co reiterated an “outperform” rating and issued a $20.00 price objective on shares of Aduro Biotech in a report on Monday, November 14th. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Monday, November 21st. Roth Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of Aduro Biotech in a report on Friday, November 25th. Finally, Leerink Swann set a $14.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Monday, October 24th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.60.

About Aduro Biotech

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

5 Day Chart for NASDAQ:ADRO

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.